REHOVOT, Israel, Aug. 25, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced that senior management will participate in the upcoming 27th Annual H.C. Wainwright Global Investment Conference on Monday, September 8^th and Tuesday September 9^th, 2025, at the Lotte New York Palace Hotel.

Investors attending the event may request a one-on-one meeting with CollPlant through their H.C. Wainwright representative or e-mail This email address is being protected from spambots. You need JavaScript enabled to view it..

About CollPlant

CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.

In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.

For more information about CollPlant, visit http://www.collplant.com.

Contacts

CollPlant:
Eran Rotem
Deputy CEO & CFO
+972-73-2325600
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investors:
LifeSci Advisors
Dan Ferry
This email address is being protected from spambots. You need JavaScript enabled to view it.